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Periodontal infections contribute to HIV-associated co-morbidities in the oral cavity and provide a model
to interrogate the dysregulation of macrophage function, inﬂammatory disease progression, and HIV
replication during co-infections. We investigated the effect of Porphyromonas gingivalis on the estab-
lishment of HIV infection in monocyte-derived macrophages. HIV replication in macrophages was sig-
niﬁcantly repressed in the presence of P. gingivalis. This diminished viral replication was due partly to a
decrease in the expression of integrated HIV provirus. HIV repression depended upon signaling through
TLR4 as knock-down of TLR4 with siRNA rescued HIV expression. Importantly, HIV expression was re-
activated upon removal of P. gingivalis. Our observations suggest that exposure of macrophages to Gram-
negative bacteria inﬂuence the establishment and maintenance of HIV persistence in macrophages
through a TLR4-dependent mechanism.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Periodontal disease is one of the most common chronic infec-
tions in the US, estimated to affect more than 100 million people
(Eke et al., 2012; Slade and Beck, 1999). Periodontal disease is
aggravated in HIV-infected patients and leads to oral complica-
tions such as necrotizing ulcerative gingivitis and ulcerative peri-
odontitis. Though anti-retroviral therapy (ART) decreases the
prevalence of periodontal disease, it does not ameliorate oral
complications in many patients. Thus, oral disease is a major co-
morbidity that affects the quality of life of HIV-infected individuals
(Patton et al., 2000; Schmidt-Westhausen et al., 2000; Tappuni
and Fleming, 2001). HIV target cells are present in the oral cavity
(Cutler and Jotwani, 2006) and how the mouth microenvironment
and the associated dysregulated inﬂammatory axis inﬂuence HIV
replication has not been thoroughly investigated.
We are interested in determining how oral pathobiontsInc. This is an open access article u
ction of Infectious Diseases,
r, Boston, MA 02118, USA.
of Medicine, Department of
of Microbiology, 650 Albanyinﬂuence the course of HIV infection and replication. Although, the
microbiology of HIV-associated periodontal disease is complex,
the Gram-negative bacterium, Porphyromonas gingivalis is an im-
portant etiological agent of disease (Hajishengallis et al., 2012;
Holt et al., 1988; Socransky et al., 1998; Ximenez-Fyvie et al.,
2000). P. gingivalis is present in sub-gingival plaques of HIV-in-
fected individuals (Cross and Smith, 1995; Pereira et al., 2014;
Tenenbaum et al., 1997) and it has been shown to activate HIV
transcription in some cell models through TLR2 and TLR9 and
through the expression of short-chain fatty acids (Das et al., 2015;
Gonzalez et al., 2010; Imai et al., 2009). These observations suggest
that HIV and P. gingivalis co-infections exacerbate oral disease.
Therefore, P. gingivalis provides a model pathogen to explore the
interactions between periodontal disease-associated microbes and
HIV infection.
Macrophages represent a diverse population of immune cells
residing within all anatomical compartments and are important
effectors of the innate immune response against microbes, mod-
ulate inﬂammatory responses and bridge the innate and adaptive
immune system through antigen presentation to CD4þ T cells
(Varol et al., 2015). In the case of periodontal disease, macrophages
represent up to 30% of the inﬁltrating immune cells in lesions
(Okada and Murakami, 1998). Furthermore, macrophages within
many anatomical compartments are susceptible to direct infection
by HIV-1 and this infection correlates with macrophagender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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pathogen killing and chemotaxis (Pugliese et al., 2005). HIV re-
plication is dependent on the regulation of transcription factors,
cytokines and anti-viral restriction factors associated with mac-
rophage activation and the cytokine microenvironment (Cassetta
et al., 2013; Cassol et al., 2009; Herbein and Varin, 2010; Koyanagi
et al., 1988; Schlaepfer et al., 2014; Schuitemaker et al., 1994;
Schuitemaker et al., 1992). However, it remains unclear to what
extent these signals affect long term HIV pathogenesis or possibly
HIV persistence. Despite the success of highly active anti-retroviral
therapy (HAART) in controlling HIV replication and preventing the
onset of AIDS in infected patients, the infection cannot be fully
eliminated due to the persistence of HIV-infected cells resistant to
therapy (Siliciano and Greene, 2011).
The population of persistently infected cells is primarily com-
prised of latently-infected resting CD4þ T cells (Brenchley et al.,
2004; Chomont et al., 2009; Chun et al., 1997; Douek et al., 2002;
Maldarelli et al., 2014; Ostrowski et al., 1999; Wagner et al., 2014),
but it has been hypothesized that macrophages and other myeloid
cells contribute to long-term viral persistence (Coleman and Wu,
2009). Two potential mechanisms could mediate persistent HIV
infection in macrophages. Macrophages are known to resist the
cytopathic effects of HIV replication and survive infection to pro-
duce low levels of viral particles (Gartner et al., 1986; Koenig et al.,
1986; Nicholson et al., 1986; Salahuddin et al., 1986; Sonza et al.,
2002). This form of persistence would be especially important if
infected macrophages reside within anatomical sanctuaries where
therapies are not present at effective concentrations. The other
possibility is that HIV provirus following infection is tran-
scriptionally silenced and provirus is reactivated upon cell stimu-
lation (Brown et al., 2006; Coleman and Wu, 2009).
To gain insights into how existing oral bacteria inﬂuence HIV
infection of macrophages, we tested whether P. gingivalis altered
the course of infection in primary monocyte-derived macrophages
(MDMs). We found that exposure to P. gingivalis at the time of HIV
infection led to repression of HIV expression despite efﬁcient viral
entry, integration and transcription. Importantly, this repression
was reversible upon removing bacteria and dependent on the re-
cognition of bacterial lipopolysaccharide (LPS) through TLR4 sig-
naling. These results suggest that exposure to P. gingivalis at the
time of HIV infection induces persistence in macrophages and
suggest that pre-existing infections play a role in the establish-
ment of HIV persistence within macrophages.2. Results
2.1. P. gingivalis inﬂuences macrophage phenotypes
In order to appreciate how P. gingivalis inﬂuences HIV replica-
tion in macrophages, it was necessary to establish whether P.
gingivalis skews macrophage phenotypes. Monocyte-derived-
macrophages (MDM) were enriched from peripheral blood and
matured on plastic for one week prior to co-culturing with heat-
killed P. gingivalis strain 381. Although this species of bacteria is
found among the normal ﬂora of the oral cavity, P. gingivalis can be
pathogenic and it is a major contributor to periodontal disease. An
advantage of using heat-killed bacteria over live bacteria is that it
reduces the complexity of the culture system by eliminating
variables associated with bacterial growth and virulence factors;
any effect on HIV replication can be directly attributed to the re-
cognition of bacteria structure by macrophages. We examined
whether bacteria altered MDM phenotype by measuring the ex-
pression of CD14, CD206 and CCR7. MDMs exposed to bacteria up-
regulated CD14 and CD206 and down-regulated CCR7 (Fig. 1).
Expression of these surface molecules has been associated withanti-inﬂammatory functions (Martinez et al., 2006).
2.2. Exposure of MDMs to P. gingivalis reduces HIV replication
To test whether HIV replication in MDMs was affected by the
presence of P. gingivalis, we inoculated MDMs with HIV in the
presence or absence of bacteria and monitored HIV replication by
p24 ELISA over time (Fig. 2A and B). HIV replication was inhibited
by up to 10-fold when P. gingivaliswas present in the culture at the
time of infection with HIV (Fig. 2B). To investigate whether this
effect in viral replication was due in part to defects in post-in-
tegration steps in the viral life cycle, we used single round en-
velope-deleted HIV pseudotyped with VSV-G encoding ﬁreﬂy lu-
ciferase or GFP. Any defects in steps post-viral integration would
indicate that exposure to P. gingivalis at the time of HIV infection
enables the establishment of persistent infection in macrophages.
We found that HIV was expressed less efﬁciently in MDMs co-
exposed to heat-killed bacteria despite similar levels of integrated
proviral DNA as measured by a nested Alu-quantitative PCR
(Fig. 2C–E). Together, these results suggest that steps post-in-
tegration are repressed when macrophages are exposed to heat
killed P. gingivalis at the time of HIV infection.
To determine whether P. gingivalis-mediated repression was
reversible, bacteria were washed out 3 days post-infection and HIV
expression was monitored over 12 days (Fig. 3). While there was a
lag of 3–6 days in HIV expression in MDMs after the removal of
bacteria, by day 12 a greater than a log increase in HIV expression
was observed (Fig. 3). These results suggest that the repression
induced by P. gingivalis is reversible and that MDMs can be per-
sistently infected.
To gain further insight into the mechanisms of repression, we
examined the level of proviral gene transcription. We found that P.
gingivalis exposure did not decrease the proportion of initiated or
elongated HIV transcripts relative to MDMs infected with HIV
alone despite a 3–5-fold reduction in HIV expression as de-
termined by luciferase expression from a parallel inoculation
(Fig. 4A and B). Instead, a 2-fold increase in the levels of both
initiated and elongated transcripts was detected. In addition, no
signiﬁcant changes in transcript splicing were observed (Fig. 4C).
This suggests that HIV expression and production is repressed at a
step post-proviral transcription. In agreement with this observa-
tion, we found that HIV expression could not be re-activated by
common latency reversing agents that target transcriptional co-
factors and chromatin remodeling complexes (Fig. 4D and E). To-
gether, these results suggest that P. gingivalis induces a state in
macrophages that represses HIV expression through a mechanism
that differs from latency described in T cells.
2.3. TLR4 mediates repression of HIV replication in MDMs exposed to
P. gingivalis
Since components of the bacterial surface are likely factors to
interact with macrophages during HIV infection in our culture
system, we investigated whether bacterial LPS is sufﬁcient to in-
duce the observed repression of HIV expression. P. gingivalis has
two dominant forms of LPS based on the acylation status of Lipid
A. LPS1435 is tetra-acylated while LPS1690 is penta-acylated
(Darveau et al., 2004). LPS1435 and LPS1690 differentially re-
pressed HIV expression, with LPS 1435 having a modest effect on
HIV replication but LPS1690 inhibiting HIV replication by greater
than 90% (Fig. 5A). This reduction in HIV expression could not be
attributed to cell death in culture and it was dependent on the LPS
dose (Fig. 5B and C). LPS derived from E. coli also signiﬁcantly
repressed HIV expression consistent with previous reports
(Ahmed et al., 2010; Equils et al., 2006; Kornbluth et al., 1989;
Simard et al., 2008). These results suggest that a common LPS-
Fig. 1. MDMs polarize in response to P. gingivalis. (A) MDMs were exposed to P. gingivalis at an MOI of 100 for 3 days and monitored surface molecule expression by ﬂow
cytometry. CCR7 expression was assessed by Western blotting. Data are representative of 3 individual experiments.
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macrophages. Both forms of the P. gingivalis LPS are recognized by
TLR2 and TLR4, but LPS1435 has a stronger bias toward TLR2
whereas LPS1690 strongly activates TLR4 mediated NF-κB signal-
ing (Darveau et al., 2004; Herath et al., 2013). Since both E. coli LPS
and LPS1690 repressed HIV expression most robustly, while
LPS1435 had a weaker repressive capacity, this implicates TLR4 in
the recognition of P. gingivalis and its ability to repress HIV. To test
the role of TLR4 in limiting HIV replication, siRNA was used to
knock-down TLR4 in MDMs. We achieved approximately 80% de-
crease in TLR4 mRNA expression (Fig. 6A). This knockdown of TLR4
was sufﬁcient to prevent P. gingivalis-mediated repression of HIV
expression (Fig. 6B). This is consistent with the inability of
Pam3CSK4, a TLR2 agonist, to repress HIV expression (Fig. 6C).3. Discussion
Macrophages are sentinel cells involved in the ﬁrst line of de-
fense during the innate immune response to the microbial mi-
croenvironment. How these interactions with commensal and
pathobiont organisms inﬂuence HIV infection and replication in
macrophages has not been thoroughly explored. We report that
the presence of the periodontal pathobiont P. gingivalis at the time
of HIV infection of macrophages signiﬁcantly represses viral re-
plication. This repression is reversible, correlates with phenotypic
changes of the macrophages and dependent on TLR4 signaling.
Our observation that HIV expression is suppressed by P. gingi-
valis LPS is consistent with published work using E. coli LPS and
other bacteria (Ahmed et al., 2010; Bernstein et al., 1991; Korn-
bluth et al., 1989; Liu et al., 2006; Simard et al., 2008). E. coli LPS
has been suggested to interfere with HIV replication at multiple
steps of the HIV replication cycle in macrophages including in-
terference of efﬁcient viral entry (Franchin et al., 2000; Herbein
et al., 1995; Herbein and Varin, 2010; Mikulak et al., 2009; Verani
et al., 1997; Verani et al., 2002) and a restriction after entry but
before proviral integration (Devadas et al., 2010; Donninelli et al.,
2016; Pushkarsky et al., 2001; Schlaepfer et al., 2014; Wang et al.,
2011). Our data suggests that a step post-proviral integration and
transcription are targeted in MDMs when infected with HIV in the
presence of P. gingivalis. Although the precise mechanism for this P.
gingivalis mediated restriction has not been identiﬁed, one can-
didate is the anti-viral activity of interferons secreted in response
to bacterial LPS (Ahmed et al., 2010; Kornbluth et al., 1989; Meylan
et al., 1993; Mosoian et al., 2010; Simard et al., 2008). However, in
our preliminary experiments P. gingivalis did not signiﬁcantlyinduce type 1 interferons and HIV expression in the presence of P.
gingivalis was not rescued by blocking INF-R1 with antibodies
(data not shown). Additional work is required to validate these
initial observations and determine the repressive mechanisms
initiated by P. gingivalis. The similarities between the suppression
of HIV expression by E. coli-derived LPS and P. gingivalis-derived
LPS1690, reﬂect a common TLR4-dependent mechanism for the
repression of HIV. This signaling through TLR4 is speciﬁc since
engaging TLR2 with the agonist Pam3CSK4 was not capable of
repressing HIV replication. This is also consistent with the mild
repressive state induced by P. gingivalis LPS1435 which tends to
signal more strongly through TLR2 rather than through TLR4
(Darveau et al., 2004; Herath et al., 2013). These results suggest
that HIV repression is not a general property of Gram-negative
bacteria.
TLR4 signaling occurs through two cascades: MyD88 and TRIF.
Signaling through MyD88 promotes pro-inﬂammatory cytokine
production (e.g. TNF-α and IL-β) whereas TRIF is upstream of type
1 IFN induction (Kawai and Akira, 2007; Mosoian et al., 2010). The
outcome of HIV expression will depend on how these two sig-
naling pathways are activated and integrated in different cell
types, and may explain contradictory observations reported on the
response of HIV expression to TLR4 ligands (Bergamaschi and
Pancino, 2010; Equils et al., 2001, 2004, 2006; Kadoki et al., 2010;
Lodie et al., 1998; Pomerantz et al., 1990). Macrophages in mucosal
tissues encounter a combination of stimuli ranging from host-
derived cytokines to various pathogen-derived TLR ligands. These
stimuli lead to various outcomes in macrophage phenotype and
behavior. For example, we found that macrophages exposed to P.
gingivalis adopt a phenotype consistent with anti-inﬂammatory
macrophages (Fig. 1). Therefore, TLR4 in speciﬁc contexts may
protect against ectopic inﬂammation. Other receptors that main-
tain tissue macrophage anti-inﬂammatory functions have been
shown to repress HIV transcription, such as the receptor tyrosine
kinase RON (Cary et al., 2013; Klatt et al., 2008; Lee et al., 2004).
We propose that the stimuli encountered by tissue macrophages
will skew the behavior of these cells, which will directly inﬂuence
the ability of the macrophages to support HIV infection, replication
or persistence. This in turn will affect HIV pathogenesis and the
resolution of opportunistic infections such as periodontitis in HIV-
infected individuals.
One important observation is that P. gingivalis as well as E. coli LPS
suppressed HIV replication in macrophages at a step after HIV entry
and integration. This repression of HIV replication in macrophages
was different than latency in T cells since it could not be reverse with
a number of latency reversing compounds (Fig. 4E). This result is
Fig. 2. The presence of P. gingivalis at the time of infection represses HIV replication in MDMs. (A) General experimental outline to test the effect of heat-killed P. gingivalis on
HIV replication in MDMs. (B) MDMs were infected with HIV-WT/BaL with or without exposure to P. gingivalis at an MOI of 10. HIV spread was monitored by HIV-p24 ELISA.
Data is representative of 3 independent experiments. To test HIV expression in the context of single round infection, MDMs were infected with HIV-NL4-3ΔEnv-Luc(VSV-G)
with or without P. gingivalis (MOI 30) and monitored HIV infection by (C) luciferase expression (D) and Alu-PCR for HIV integration at 3 days post-infection. Cultures treated
with 1 mM efavirenz (EFV) served as a negative control. Error bars represent the standard deviation of triplicate measurements. Both graphs were generated from the same
experiment and are representative of 3 individual experiments. Asterisks and NS represent po0.01 and p40.05 respectively as assessed by Student's T test. (E) MDMs were
infected with HIV-NL4-3ΔEnv-GFP(VSV-G) and monitored GFP expression 3 days post-infection by ﬂow cytometry. Percentages are displayed7the standard deviation of
triplicate infections of cells from the same donor. The geometric mean intensity of GFP (MFI) is displayed7the standard deviation of triplicate inoculations of cells from the
same donor. The experiment is representative of 3 individual experiments.
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is post-transcriptional and this overrides efﬁcient HIV transcription
in P. gingivalis-treated macrophages. This has important implications
for the development of “shock and kill” approaches to cure, since
persistent HIV infection in macrophages induced by TLR signaling
would not be susceptible to latency reversing compounds.
In conclusion, our studies suggest that exposure of MDM to
bacterial products promotes HIV infection but inhibits replicationthrough a TLR4-mediated mechanism. Since this repression is re-
versible and macrophages are long lived cells that are resistant to
the cytopathic effects of HIV replication, this may provide a me-
chanism for macrophages to contribute to the viral load of differ-
ent tissues upon anti-retroviral treatment interruption. These
studies also provide insights into the complex interplay between
macrophage function, pre-existing microbiota and HIV and their
role in HIV infection and inﬂammation.
Fig. 3. HIV expression rebounds after removal of bacteria. MDMs were infected
with HIV-NL4-3ΔEnv-Luc(VSV-G) with P. gingivalis for 3 days followed by removal
of bacteria. HIV expression was monitored by luciferase expression every 3 days.
Error bars represent the standard deviation of infections done in triplicate.
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4.1. Puriﬁcation and differentiation of monocyte derived
macrophages
Peripheral blood mononuclear cells (PBMC) were isolated from
de-identiﬁed human leukapheresis-processed blood (New York
Biologics, Inc) by centrifugation through Histopaque-1077 (Sigma
Aldrich, Inc.) density gradient. Brieﬂy, room temperature blood
was diluted with an equal volume of room temperature PBS (In-
vitrogen). 35 ml of diluted blood was then layered over 15 ml of
room temperature Histopaque-1077 and spun at 1500 rpm for
30 min at room temperature in a bench top centrifuge. PBMC layer
was removed and washed 3 times with PBS. Excess red blood cells
were lysed by resuspending the cell pellet in room temperature
lysis buffer (155 mM NH4Cl, 12 mM NaHCO3, 0.1 mM EDTA in
water) for 1–2 min. To purify and differentiate MDMs, PBMC were
resuspended in RPMI (Invitrogen) without serum at a density of
5106 cells/ml and plated 10 ml per 10 cm tissue culture dish.
Cells were incubated at 37 °C for 1–2 h to allow binding of
monocytes to the plates. The plates were then swirled to re-
suspend unbound cells and these cells were discarded. The bound
cells were cultured in RPMI supplemented with 10% fetal bovine
serum (FBS) (Corning, Inc.), 10% human AB serum (Gemini Bio-
Products), 100U/ml of penicillin/streptomycin (Invitrogen) and
2 mM L-glutamine (Invitrogen). MDMs were allowed to differ-
entiate for a week at 37 °C and spent medium containing unbound
cells was removed and replaced with fresh medium every 2–3
days. To prepare differentiated MDMs for inoculations, the cells
were washed twice with PBS to remove contaminating lympho-
cytes followed by treatment with Versene (Invitrogen) at 37 °C for
10–20 min. To lift the MDMs from the plates, we pipeted Versene
directly onto the cells and gently scraped the cells that were still
attached.
4.2. Viruses
Viruses were generated by transfecting HEK293T cells (cultured
in DMEM supplemented with 10% FBS, 100U/ml of penicillin/
streptomycin and 2 mM L-glutamine) by calcium-phosphate pre-
cipitation using plasmids encoding the following HIV-1 clones:pNL4-3. Luc. R-E- (NIH AIDS Reagents Program), NL4-3ΔEnv-GFP
or pWT/BaL (NIH AIDS Reagents Program). Viruses defective in the
envelope glycoprotein were pseudotyped with VSV-G. Viruses
were typically concentrated by ultracentrifugation over a cushion
of 10% sucrose solution in PBS at 19,000 rpm for 1.5 h at 4 °C.
4.3. Cultivation of P. gingivalis
P. gingivalis strain 381 was used in these studies and was cul-
tured as previously described (Shaik-Dasthagirisaheb et al., 2014).
In brief, bacteria were grown on anaerobic blood agar plates for 4–
6 days, and placed into brain-heart infusion (BHI) broth for 24 h
growth. Bacteria were harvested by centrifugation, washed, and
suspended in PBS to OD660 of 1.0 (1109 colony forming units
(CFU)/ml). Bacterial culture purity was conﬁrmed by Gram stain-
ing. Heat-killed P. gingivalis preparations were generated by in-
cubating an aliquot at 60 °C for 30 min; plate counts were used to
conﬁrm killing.
4.4. HIV infection of MDMs
MDMs were plated at 30,000 cells per 100 μl of medium per
well in 96-well plates the day prior to infection with HIV. Cells
were typically infected overnight by adding 50 μl of virus at
roughly an MOI of 1 based on TZMbl infectivity (NIH AIDS Re-
agents Program) with or without heat-killed P. gingivalis, puriﬁed
LPS from P. gingivalis (LPS1435 or LPS1690 from Astarte Biologics)
or puriﬁed E. coli LPS (Sigma). MDMs infected in the presence of
1 μM of the reverse transcriptase inhibitor efavirenz (NIH AIDS
Reagents Program) served as negative controls. After overnight
incubation, the wells were washed with 200 μl of PBS and added
fresh medium with or without bacterial products. The cultures
were incubated for another 3 days and harvested for HIV infection
analysis. When longer incubation periods were necessary, half of
the medium was replaced with fresh medium every 2-3days.
4.5. Luciferase expression and viability
For measuring HIV expression based on luciferase, the cells
were lysed with 20 μl of 1x Luciferase Cell Culture Lysis Reagent
(Promega) at room temperature for 20 min. The lysate was
transferred to clear bottom, black-walled 96-well plates, added
20 μl of luciferase substrate (Promega) and read with a BioTek
Synergy HT plate reader at 1 s per well. Cell viability was assessed
in infection done in parallel in clear bottom black-walled 96-well
plates. 3 days post-infection, the supernatant was removed from
the wells, the wells were washed with PBS once and added 20 μl
of fresh medium with 20 μl of CellTiter-Glo (Promega). The cells
were incubated at 37 °C for 10 min followed by reading lumines-
cence with a BioTek Synergy HT plate reader at 1 s per well.
4.6. Measuring HIV titers with ELISA
Culture supernatants were diluted in PBS supplemented with
20%FBS and 1% Triton-X and subsequently bound to a 96-well
plate coated with anti-HIV immunoglobulin (AIDS Reagent Pro-
gram catalog number 3957). Antibodies from the culture super-
natant of hybridoma cells speciﬁc for HIV p24 were used as pri-
mary antibodies (AIDS Reagent Program catalog number 183-H12-
5C). This was followed by a HRP coupled anti-mouse secondary
antibody (Santa Cruz). Detection of color change of TMB SureBlue
(KPL) solution was measured in a TECAN microplate reader at
450 nm, followed by quantiﬁcation against a commercially avail-
able p24 standard (eEnzyme).
Fig. 4. P. gingivalismediated repression of HIV is post-transcriptional. MDMs were infected with HIV-NL4-3ΔEnv-Luc(VSV-G) for 4 h in the presence or absence P. gingivalis at
an MOI of 30. (A) The cells were collected 3 days post-infection to measure HIV expression by luciferase. Error bars represent the standard deviation of 3 infections. In a
parallel infections, the cells were harvested to measure the levels of (B) initiated and elongated HIV transcripts and (C) multiply- and singly-spliced HIV transcripts by RT-
PCR. Error bars represent the standard deviation of measurements done in triplicate. The data shown is representative of 2 independent experiments. (D) Latency reversing
compounds were used to reactivate repressed HIV in MDMs exposed to P. gingivalis. After removing the bacteria and culturing MDMs in the absence of bacteria for 3 days, the
cells were exposed to a panel of stimulating agents for 24 h and followed by analysis of luciferase expression (E): bryostatin (10 nM), trichostatin A (100 nM), SAHA (10 μM),
and JQ1 (10 μM). Error bars represent the standard deviation of measurements done in triplicate. The data is representative of more than 3 experiments.
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MDMs were cultured in a 24-well plate in the presence or
absence of P. gingivalis at an MOI of 100 for 3 days. The cells were
then treated directly in the culture plate with 100 μl of FACS buffer
(PBS supplemented with 2 mM EDTA and 0.5% bovine serum al-
bumin) supplemented with human serum at 10% for 10 min at
room temperature to block Fc-receptors. The cells were then
stained with anti-CD206 (clone 19.2, BD Biosciences), anti-CD14
(clone M5E2, BD Biosciences) or isotype controls (BD Biosciences),
and incubated for 15 min at room temperature. The cells were
then washed twice with FACS buffer, resuspended in FACS buffer
supplemented with 1% paraformaldehyde and transferred to ﬂow
cytometry tubes for analysis with a FACSCalibur instrument (BD
Biosciences).4.8. Western blotting
Cells were lysed with RIPA buffer (Thermo Scientiﬁc). Proteins
were separated on a 12% SDS-PAGE gel and transferred to a ni-
trocellulose membrane. CCR7 was detected with a monoclonal
antibody (Abcam) and a secondary antibody coupled to a ﬂuor-
ophore using a Li-cor Odyssey system. The amount of protein for
each lane was normalized to GAPDH (cell signaling).
4.9. Measuring HIV integration
Macrophages infected with HIV in vitro were treated with
DNAse-I (50 μg/ml) in the presence of 10 mM of MgCl2 for 30 min
to remove residual HIV plasmid DNA from the medium. The cells
were then removed from the plates and the genomic DNA was
L.M. Agosto et al. / Virology 499 (2016) 72–8178puriﬁed using the DNeasy Blood and Tissue kit (Qiagen). Genomic
DNA was eluted with 10 mM Tris-HCl (pH8.0) buffer. Prior to
measuring HIV integration, the number of cells represented in the
DNA samples was estimated by quantitative PCR ampliﬁcation ofhuman albumin as similarly done previously (Agosto et al., 2007).
DNA from uninfected PBMC was used as a standard with the es-
timation that 10 μl of 24 μg/ml of DNA sample equals 34,800 cells.
The reaction conditions were 10 μl of DNA sample diluted in
10 mM Tris-HCl buffer (pH 8.0) with 10 μl of master mixture at 2x
concentration: 2x PCR buffer (40 mM KCl, 40 mM Tris-HCl (pH 8),
10 mM (NH4)2SO4), 11 mM MgCl2, 2.4 mM of dNTP mix (0.6 mM of
each dATP, dCTP, dGTP and dTTP), 0.52 mM of forward primer 5′-
GCTGTCATCTCTTGTGGGCTGT-3′ (Invitrogen), 0.52 mM of reverse
primer 5′-AAACTCATGGGAGCTGCTGGTT-3′ (Invitrogen), 0.4 mM of
probe 5′-FAM-CCTGTCATGCCCACACAAATCTCTCC-TAMRA-3′ (In-
tegrated DNA Technologies) and 1.25U of Maxima Hot Start Taq
Polymerase (Fisher Scientiﬁc). The reaction was run in a Quant-
Studio 3 (Applied Biosystems) with the following program: hot-
start at 95 °C for 2 min, followed by 50 cycles of denaturation for
15 s at 95 °C, annealing for 30 s at 60 °C, plate read and extension
for 1 min at 72 °C.
HIV integration was measured by nested Alu-PCR as similarly
described (Agosto et al., 2007). The DNA samples were diluted in
10 mM Tris-HCl (pH 8.0) and adjusted to a total DNA concentration
of 2 mg/ml using uninfected PBMC DNA. This corresponds to
roughly 3,000 cells per 10 μl of DNA sample. Samples were pre-
ampliﬁed alongside an integration standard made from a poly-
clonal cell line carrying a single integrated copy per cell starting at
a total DNA concentration of 3 mg/ml (Liszewski et al., 2009). The
integration standard was serially diluted 5-fold in 10 mM Tris-HCl
(pH 8.0) containing 2 mg/ml of uninfected PBMC DNA in order to
maintain the total DNA concentration constant. The samples are
pre-ampliﬁed with primers speciﬁc for cellular Alu and viral gag:
genomic Alu forward 5′ GCC TCC CAA ACT GCT GGG ATT ACA G-3′
and HIV gag reverse 5′-GCT CTC GCA CCC ATC TCT CTC C-3′. The
reaction conditions were 10 μl of DNA sample with 10 μl of master
mixture at 2x concentration: 2x PCR buffer (40 mM KCl, 40 mM
Tris-HCl (pH 8), 10 mM (NH4)2SO4), 11 mM MgCl2, 1.68 mM of
dNTP mix (0.42 mM of each dATP, dCTP, dGTP and dTTP), 0.24 mM
of Alu forward primer, 1.2 mM of gag reverse primer and 1.25U of
Maxima Hot Start Taq Polymerase (Fisher Scientiﬁc). A parallel
reaction without forward primer for Alu was done for each sample
as a control for unintegrated HIV DNA. The reaction was conducted
in a Biometra T-Professional thermocycler with the following
program: hot start at 95 °C for 4 min and 20 cycles of 93 °C for
15 s, 50 °C for 15 s and 70 °C for 2.5 min 10 μl of the reaction
products from samples and standard were transferred to another
plate containing 10 μl of the following 2x master mixture speciﬁc
for the RU5 region of the HIV LTR: 2x PCR buffer (40 mM KCl,
40 mM Tris-HCl (pH 8), 10 mM (NH4)2SO4), 11 mM MgCl2, 2.4 mM
of dNTP mix (0.6 mM of each dATP, dCTP, dGTP and dTTP), 0.52 mM
of forward 5′-GCC TCA ATA AAG CTT GCC TTG A-3′, 0.52 mM of
reverse 5′-TCC ACA CTG ACT AAA AGG GTC TGA-3′ primers, 0.4 mM
of probe 5′-FAM-CCAGAGTCACACAACAGACG-TAMRA-3′ (In-
tegrated DNA Technologies) and 1.25U of Maxima Hot Start TaqFig. 5. LPS from P. gingivalis is sufﬁcient to repress HIV expression. (A) MDMs were
infected with HIV-NL4-3ΔEnv-Luc(VSV-G) with or without P. gingivalis (MOI 30),
puriﬁed P. gingivalis LPS1435 (1 μg/ml), puriﬁed P. gingivalis LPS1690 (1 μg/ml) or E.
coli LPS (10 ng/ml) following the outline in Fig. 2A and monitored luciferase ex-
pression at 3 days post-infection. Cultures treated with 1 mM efavirenz (EFV) served
as a negative control. Error bars represent the standard deviation of triplicate
measurements. Data is representative of more than 3 individual experiments.
(B) Cell viability was monitored using CellTiter-Glo and represents the viability
relative to the EFV-treated cells. Graph was generated from a parallel infections as
the experiment in (A). Error bars represent the standard deviation from triplicate
measurements. The data is representative of 2 individual experiments. (C) MDMs
were infected with HIV-NL4-3ΔEnv-Luc(VSV-G) with or without serial dilutions of
P. gingivalis and E. coli LPS. Error bars represent the standard deviation of mea-
surements done in triplicate. The data is representative of 2 independent
experiments.
Fig. 6. Knock-down of TLR4 rescues HIV expression. MDMs were transfected with siRNA against TLR4 or a non-targeting control. (A) Conﬁrmed TLR4 down-regulation by RT-
PCR 48 h post-transfection. Error bars represent the standard deviation of triplicate measurements. (B) Cells were infected with HIV-NL4-3ΔEnv-Luc(VSV-G) 72 h post-
transfection under the conditions shown following the experiment outline in Fig. 1A and measured HIV expression by luciferase 3 days post-infection. Error bars represent
the standard deviation of triplicate infections. (C) Engaging TLR2 with the agonist Pam3CSK4 (1 μg/ml) does not repress HIV expression to a similar extent as E. coli LPS (1 μg/
ml). Error bars represent the standard deviation of infections done in triplicate and the data is representative of more than 3 independent experiments.
L.M. Agosto et al. / Virology 499 (2016) 72–81 79Polymerase (Fisher Scientiﬁc). The transferred samples and stan-
dard were ampliﬁed alongside a pNL4-3 copy standard and in-
tegration standard that had not been pre-ampliﬁed. The PCR was
conducted in a QuantStudio 3 (Applied Biosystems) with the same
program as the albumin assay described above. The data was
analyzed by plotting the total number of molecules calculated for
each dilution of the not-pre-ampliﬁed integration standard versus
the cycle threshold determined for each dilution of the pre-am-
pliﬁed integration standard in a natural log scale. The linear curve
generated was used to calculate the total number of integration
events per sample based on reaction cycle threshold. To calculate
the number of integration events per cell, used the cell number
pre-determined based on the albumin assay described above.
4.10. siRNA knock-down
ON-TARGETplus SMART-pool siRNA (GE Dharmacon) was used
to knock-down human TLR4 in MDMs. The siRNA pool targets the
following regions of TLR-4 transcripts: 5′-UGGUGGAAGUU-
GAACGAAU-3′, 5′-GUUUAGAAGUCCAUCGUUU-3′, 5′-CAUUGAA-
GAAUUCCGAUUA-3′, and 5′-GGAAAAUGGUGUAGCCGUU-3′. ON-
TARGETplus Non-targeting Pool siRNA (GE Dharmacon) was used
as the negative control. The control siRNA targets the following
sequences: 5′-uggUUUACAUGUCGACUAA-3′, 5′-UGGUUUACAU-
GUUGUGUGA-3′, 5′-UGGUUUACAUGUUUUCUGA-3′, and 5′-UG-
GUUUACAUGUUUUCCUA-3′. For transfection of siRNA, MDMs were
plated in 10 cm dishes at 3–7106 cells per dish the night before
transfection. The following morning, the medium was replaced
with 10 ml of medium without antibiotics. In the afternoon, the
cells were transfected using Lipofectamine 2000 as follows.
600 pmol of siRNA duplexes were diluted in 900 μl of OptiMEM
(Invitrogen) in a tube. In a separate tube, added 60 μl of Lipo-
fectamine 2000 (Invitrogen) to 900 μl of OptiMEM. Incubated both
tubes at room temperature for 5 min. The diluted siRNAwas added
to the contents of tube 2 and mixed by pipeting gently 3 times.
Incubated the transfection mixture at room temperature for10 min. Added to cultured cells and swirled the plate to mix. After
overnight incubation at 37 °C, the supernatant was removed and
added fresh medium containing antibiotics. The cells were har-
vested 48 h later and plated for HIV infection the following day. A
subset of the cells was lysed with TRIzol (Invitrogen) for RNA
analysis of TLR4 expression.
4.11. RNA extractions
MDM pellets were resuspended in 1 ml of TRIzol, added 200 μl
of chloroform and mixed by vortexing. The samples were then
incubated at room temperature for 5 min and spun at 12,000g for
15 min at 4 °C. The top aqueous layer was transferred to a separate
tube and mixed with 500 μl of isopropanol (AmericanBio, Inc.) and
mixed gently by inverting the tube to precipitate RNA. The sam-
ples were incubated at room temperature for 5 min followed by
centrifugation at 12,000g for 10 min at 4 °C. The supernatant was
removed and the pellet was washed with 70% ethanol solution
(AmericanBio, Inc.). The supernatant was removed and let the RNA
pellet dry at room temperature. Once dried, the pellet was re-
suspended in typically 30 μl of nuclease-free water (Ambion). The
RNA concentration in the samples was determined using a Na-
noDrop 2000 spectrophotometer (Thermo Scientiﬁc).
4.12. Generation of cDNA
500 ng of RNA was typically used to generate cDNA libraries
from each sample. The RNA was mixed with 8.3 μg/ml of random
primers (Promega) and 0.83 mM of dNTP mix (Thermo Fisher
Scientiﬁc) in a ﬁnal volume of 12 μl. Parallel aliquots for each
sample were prepared which did not receive reverse transcriptase
and were used as negative controls for genomic DNA contamina-
tion. The samples were then incubated at 65 °C for 5 min followed
by a 10 min incubation at room temperature prior to adding 8 μl of
the reverse transcriptase reaction mixture. The reverse tran-
scriptase mixture comprised the following: 2.5x First Strand Buffer
L.M. Agosto et al. / Virology 499 (2016) 72–8180(Invitrogen), 0.025 M DTT (Invitrogen), 0.5U/μl of RNaseOUT (In-
vitrogen) and 12.5U/μl of SuperScript-II enzyme (Invitrogen) all in
nuclease-free water. The same mixture without SuperScript-II
enzyme was used for the genomic DNA control samples. The re-
action was conducted in a Biometra T-Professional thermocycler
with the following program: 42 °C for 50 min followed by 70 °C for
15 min. The cDNA was stored at 20 °C until needed.
4.13. Quantitative PCR analysis of cDNA
2 μl of cDNA samples were mixed with 10 μl of GoTaq master
mixture (Promega) for PCR ampliﬁcation and analysis. The master
mixture was prepared as follows: 7.5 μl of GoTaq master mixture,
1.25 μl of each forward and reverse primers pre-diluted at 5 μM.
The primer sets used were the following: actin-forward – 5′-
TGGGACGACATGGAGAA-3′, actin-reverse – 5′-GGGTGTTGAAGGT
CTCAAA-3′, HIV initiated transcription-forward – 5′-GGGTCTCT
CTGGTTAGA-3′, HIV initiated transcription-reverse – 5′-
AGAGCTCCCAGGCTCA-3′, HIV elongated transcription-forward – 5′
GGAGCCAGTAGATCCTAGAC-3′, HIV elongated transcription-re-
verse – 5′-CTTGGCAATGAAAGCAACAC-3′, TLR-4-forward – 5′-
CCTCAGTCTGCTTGTAGTATC-3′, TLR-4-reverse – 5′-CATCCTGGCTT-
GAGTAGATAAC-3′. The PCR program was the following: hot start
for 15 min at 94 °C, followed by 45 cycles of 15 s at 94 °C, 30 s at
60 °C, 30 s at 72 °C and plate read. Relative HIV transcription and
TLR-4 expression was calculated using the ΔΔCt method (Livak
and Schmittgen, 2001).Acknowledgments
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